Ax-101 is an immune system modulatory compound, the First-in-Human Trial showed no adverse effects and efficacy in multiple cancers.
Value Focus
Ax-101 boosts the immune system so our immune system can destroy more cancer during this temporary blockade.
Proven Cancer Targets as a Single Agent
Lymphoma
Multiple Myeloma
Prospective Cancer Targets for Combination Therapy
Bladder
Colorectal
Non-Small Cell Lung
Hepatocellular
Triple-Negative Breast
Ax-101 activates and strengthens the immune system, extending its effectiveness to destroy cancer cells. In combination with Anti-PD-1 drugs destroys more cancer during the temporary blockade of the Anti-PD-1 drug. Ax-101 results in longer life and increased number of Complete Response (CR).
Improving Outcomes
In human trials as a single agent, Ax-101 shows safety, tumor shrinkage, restored DTH and measurable increased lethality to cancer.
Synergistic Effect
In animal trials as a combination therapy, Ax-101 has been proven effective against multiple cancers including bladder, colon, melanoma and lymphoma.
Favorable Risk vs. Benefit
Little apparent downside risk to Ax-101/ICI co-therapy, but significant upside potential for better outcomes, including cures.